INTRODUCTION
============

Scorpion envenomation has lead to the study of biochemical and pharmacological actions of the toxic components of scorpion venom. This has resulted in a better understanding of the envenomation syndrome, and to improve the treatment. Antivenom immunotherapy remains the only specific treatment for scorpion envenomations. The optimization of toxin neutralization by specific antibodies depends on the pharmacokinetics of both the antibody and the toxin molecules, and the capacity of the specific antibodies to sequester the toxin. Thus, the improvement in immunotherapeutic envenomations requires a better understanding of scorpion venom pharmacokinetics ([@CIT0018]).

Experimental toxicokinetic studies of *Androctonus amoreuxi*, *Tityus serrulatus*, *Buthus occitatanus tunetanus*, *Leiurus quinquestriatus*, *Buthotus judaicus*, *A. mauretanicus mauretanicus* and *A. crassicauda* radiolabeled venom have been performed after intravenous or subcutaneous injections in rabbit, guinea-pig and rat models ([@CIT0011]; [@CIT0012]; [@CIT0013]; [@CIT0024]; [@CIT0014]; [@CIT0017]; El Hafny et al, 2002). Most of these studies used employed measurement of radioactivity levels in blood, which showed bi- or tri-compartmental pharmacokinetics depending upon the scorpion species and the injection route.

The Iranian polyvalent antivenom is produced by the Razi Vaccine and Serum Production and Research Institute through the immunization of horses against the 6 medically important scorpion species in Iran: *O. doriae, Mesobuthus eupeus, Androctonus crassicauda, Buthotus (Hottentota) Saulcyi, Buthotus sach* and *Hemiscorpius lepturus* ([@CIT0019]). The antivenom contains a dilution of the F(ab′)~2~ fraction of equine immunoglobulins obtained after double saline precipitation and pepsin digestion.

However, to-date no information of pharmacokinetic parameters of the Iranian scorpion venom and Razi Institute polyvalent antivenom is available. Currently, the scorpion sting victims in Iran, including those of *O. doriae* sting, are treated with intramuscular administration of antivenom. The scope of the present study is to determine the pharmacokinetics of the *O. doriae* venom in experimentally envenomed rats as well as the pharmacokinetics of the available antivenom to evaluate, or optimize, the available therapies and routes of administration.

MATERIALS AND METHODS
=====================

Animals
-------

The male rats weighing 250-300gm were from Razi Institute (Karaj, Tehran). All pharmacokinetic experiments were conducted in accordance with principles and guidelines of the \"European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes and the Guiding Principles in the Use of Animals in Toxicology\" which were adopted by the Society of Toxicology in July1989 and revised in March 1999.

Materials
---------

The CNBr-activated Sepharose and Sephadex G~50~ were purchased from Pharmacia (Uppsala, Sweden). CM-Sepharose was from Sigma (St Louis, MO, USA). Sodium dodecyl phosphate, Hydrogen peroxide, potassium phosphate buffer, sulforic acid, sodium sulfate, phenylenediamine and Tris-buffer were from Merck (Darmastadt, Germany). The Agar gel and immunoglobulin fragments against scorpion from horse were purchased from Razi institute (Karaj, Iran). *O. doriae* lyophilized venom and antivenom were prepared in Razi institute. Venom was collected by electrical stimulation, extracted with water, freeze-dried and stored at -20^o^C until further use ([@CIT0020]).

Radioiodination of the venom and antivenom
------------------------------------------

Radio-iodination of venom and antivenom were carried out using the chloramin-T method. This method specifically iodinates tyrosine residues in proteins forming a stable covalent protein-^131^I bond. The method is generally accepted to be mild enough so as not to affect the activity of the protein being labeled ([@CIT0008]; [@CIT0007]). Briefly, 0.3mCi (300μl) of ^131^I was added to 30μl of deionized H~2~O. Then the following solutions were added in sequence: 3.5mg of venom in 300μl of 0.5M phosphate buffer, pH 7.2-7.4, 100μl of 6mg/ml chloramine-T; and 100μl of 6mg/ml sodium metabisulfite. Buffers were used to control the pH of solution for optimum efficiency of the proteins. To separate unincorporated ^131^I from the iodinated venom, a column packed with Sephadex G50 ([@CIT0021]) collected the labeled venom in 1ml fractions.

Blood Sampling
--------------

Six groups, consisting of three rats each, were sacrificed at 10, 20, 40, 60, 120, 360 and 1440min following SC administration of 5µg venom supplement with trace amounts of ^131^I. The same groups of rats were sacrificed at 5, 10, 40, 60, 120 and 360 min following IM administration of 0.2ml available antivenom supplement with trace amount of ^131^I. The rats received water and food *ad libitum*. The time course of venom concentration in the plasma was followed by radioactivity. Samples of whole blood were collected in tubes containing ethylenediaminetetraacetic acid (EDTA) as anticoagulant (final concentration 0.05M), immediately before and at regular time intervals after the end of the administrations. The concentration of scorpion ^131^I-labeled *O. doriae* venom in plasma was determined after trichlroacetic acid (TCA) precipitation. Plasma samples (50-100μl) were added to 450 or 400μl of immunoglobulin from horses and then precipitated with 500μl of 20% (v/v) TCA. After a 30-60min incubation period, mixtures were centrifuged for 15min, and the radioactivity was measured in the pellet in a γ-counter (Pharmacia, Uppsala, Sweden). The results are presented as percent injected dose/ml blood. The percent radioactivity data were presented after conversion to ng/ml.

Determination of pharmacokinetic parameters
-------------------------------------------

The plasma concentration vs time data was subjected to a non-compartmental pharmacokinetic analysis to obtain an estimate of various pharmacokinetic parameters, such as total body clearance (CL/F), distribution volume (V~d~/F), area under the curve (AUC), and mean residence time (MRT). The area under the plasma concentration versus the time curve (AUC) was calculated using the linear trapezoidal rule with extrapolation to infinity. Cl/F, MRT and V~ss/F~ were calculated using the following non-compartmental equations ([@CIT0018]):

MRT = AUMC/AUC

Cl/F = Dose/AUC

V~ss~ = Cl/F x MRT

Whereas, AUMC (area under the first moment curve) is the area under the Cxt plotted against *t* from time 0 to infinitive.

Statistical analysis
--------------------

All values were presented as mean ± standard deviation. The means were calculated from at least three separate experiments. The significance of the data was analyzed by the two-tailed unpaired or paired Students\' test. The level of significance was set at P \< 0.05.

RESULTS
=======

Pharmacokinetics of the *O. doriae* venom
-----------------------------------------

The result of the pharmacokinetic analysis, performed in three groups of rats after SC injection of the 5µg venom dose, are shown in [Figure 1](#F1){ref-type="fig"}, and the corresponding pharmacokinetic parameters are noted in [Table 1](#T1){ref-type="table"}. The time to reach the maximal venom concentration in the blood, Tmax, was virtually brief (about 2hr) and the apparent terminal half-life was 496min.

![Plasma concentration-time profile of venom after SC administration of 5µg of *O. doriae* venom supplemented with trace amount of radiolabeled ^131^I. Data are reported as means ±SEM (N = 3).](JVR-01-048-g001){#F1}

###### 

Phamacokinetic parameters of *O. doriae* venom determined after sc injection of 5µg/ml venom in rat.

  Toxicokinetic parameters of venom   Value (mean ± SEM)
  ----------------------------------- --------------------
  T~max~ (min)                        120 ± 8
  C~max~ (ng/ml)                      16.42 ± 3.2
  AUC~last~ (ng/min/ml)               11175 ± 652
  T~Half\ life~ (min)                 496.53 ± 46
  AUC~INF~ (ng/min/ml)                503.486 ± 46
  V~d/~F (ml/kg)                      1522 ± 135
  Cl/F (ml/kg/min)                    2.12 ± 0.2
  MRT (min)                           555.77

The pharmacokinetics of the venom showed that after a rapid ascending phase, which means a fast absorption of scorpion toxins, the toxin concentrations in plasma reached a maximal value (C~max~) after T~max~ of 120min. Then the curve followed a rather slow bi-phasic decline, followed by a slow and a more slowly declining phase ([Figure 1](#F1){ref-type="fig"}).

Pharmacokinetics of the antivenom
---------------------------------

Pharmacokinetic parameters of antivenom determined after an IM injection of antivenom by measurement of radioactivity method are shown in [Table 2](#T2){ref-type="table"}. AUC~last~ and C~max~ were at about 14x and 3x higher, respectively, in antivenom pharmacokinetic if compared with venom values. The C~max~ was reached earlier in antivenom (T~max~ = 60 vs 120min). V~d~ and MRT of antivenom were lower and higher, respectively, than venom in the pharmacokinetic parameters obtained. The time course of antivenom concentration in plasma, determined by radioactivity measurements, showed a bi-exponential decline ([Figure 2](#F2){ref-type="fig"}), indicating that the antivenom was distributed into two compartments with a terminal half-life (t~1/2~) of 496.43min.

###### 

Phamacokinetic parameters of antivenom determined after IM injection of 0.2ml of Razi polyvalent antivenom in rat.

  **Toxicokinetic parameters of antivenom**   **Value** (mean ± SEM)
  ------------------------------------------- ------------------------
  T~max~ (Min)                                60 ± 6
  C~max~ (ng/ml)                              48.9 ± 4.6
  AUC~last~ (ng/min/ml)                       147962.5 ± 24356
  T~Half\ life~ (min)                         902.13
  AUC~INF~ (ng/min/ml)                        2500.19 ± 325
  V~d/F~ (ml/kg)                              666.66 ± 115
  Cl/F (ml/kg/min)                            0.512 ± 0.08
  MRT (min)                                   1292.87

![Plasma concentration-time profile of antivenom F(ab\')2 after intramuscular administration of 0.2ml of antivenom supplemented with trace amount of radiolabeled ^131^I-*O. doriae* venom to rat. Data are reported as means ± SEM (N = 3).](JVR-01-048-g002){#F2}

DISCUSSION
==========

Despite the development of improved antivenom preparations and the conviction widely shared among clinicians that the antivenom therapy is the most effective treatment of severe cases of scorpion envenomations, the use of such specific treatment is still justified mainly on the basis of empirical observations. The knowledge of the neutralization capacity and kinetics of scorpion venom and antivenom can contribute to the improvement of the treatment strategies. Achieving such a goal is directly dependent upon the efficacy of specific bindings of the circulating toxins to the antivenom, and on the kinetics of both the venom and anitvenom to move from the extravascular compartment to the vascular ones, or possibly both. The antivenom used in serotherapy should possess pharmacokinetic characteristics enabling it to distribute rapidly enough to neutralize the venom fraction distributed to tissues. Pharmacokinetics contributes to the understanding of the relationship between dose and response in the design of new therapies and/or modifications of the current medicinal products.

Most of the reported scorpion venom pharmacokinetic studies were performed using ^125^I-labeled venom ([@CIT0009]; [@CIT0013]; [@CIT0024]; Calderone-Aranda et al, 1999) or by following toxin concentration by ELIZA ([@CIT0024]; [@CIT0025]; Kirifi et al, 2001; El-Hafney et al, 2002). In the current study, venom pharmacokinetics was followed by measuring TCA perceptible radiolabeled toxins in experimentally envenomed rats. Indeed, after the injection, the *in vivo* degradation of radioiodinated venom proteins could yield toxin fragments and/or free radioactive iodine, which might bind non-specifically to the plasma proteins still measured by this method. The free and non-specific plasma radioactivities and/or the degraded radio labeled venom toxins are still being quantified by the radioactive method; while ELIZA could not detect those. The ELISA assay could present limitations and disadvantages, such as the relative insensitivity, the failure to detect the venom antigen by slight modification in the body and the antibody binding sites are mostly different from the pharmacologic active ones, *etc*. These disadvantages could be limited by an accurate standardization of the assay ([@CIT0017]).

In the present study, 5µg *O. doriae* venom and 0.2ml antivenom were administered via SC and IM, respectively. The adjusted dose of venom, as the result of a scorpion sting, was the same as the amount that was injected. Also, 0.2ml of the antivenom injection was adjusted to the rats, since in the current Iranian protocol, 2 vials of 5ml antivenom are recommended for an adult.

As shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} the volume of distribution of antivenom was 666ml/kg, which is significantly lower compared to the V~d~ of venoum determined after SC injection (1522ml/kg). Considering the T~max~ values, the venom was absorbed slowly compared to the antivenom and its maximal concentration reached 1hr after the antivenom. This slow absorption may explain the delay onset of the clinical signs after an *O. doriae* sting. The antivenom F(ab′)2 had a higher rate of entry into the systemic circulation and a more extended elimination half-life. Thus, it is anticipated that antivenom would efficiently neutralize the venom following the administration of IM.

Furthermore, ^131^I-antivenom showed higher C~max~ and AUC~last~ values and an earlier T~max~ following the IM administration, indicating a faster absorption and higher uptake than the venom. The increased uptake of the antivenom can also be explained on the basis of a higher absorption rate for the antivenom, explaining the lower value found for T~max~. It is noteworthy that the values of the AUC determined after the IM administration of 5µg venom are close to those presented by Krifi and colleagues study that used the IV route.

With regards to the antivenom, we found an elimination half-life of 15hr after IM injection, which is significantly longer than the reported values for the intravenously administered *Andrectonus mauretanicus mauretanicus* ([@CIT0005]), *C. limpidus limpidus* ([@CIT0004]) and *B. occitanus mardoche* (Pepin-Covatta et al, 1996) antivenoms. Furthermore, the AUC determination of the antivenom is higher than that of the venom, which differs significantly. Therefore, these observations indicate a complete absorption of antivenom (and/or venom) from its injection site.

The V~d~ indicating a fast distribution of the venom into tissues occurred in a large extravascular compartment. As expected, the V~d~/F for the venom was higher indicating a possible increased distribution. The Cl~F~ of venom was 2.12ml/kg/min, indicating its rapid elimination. These findings suggest a fast clearance of the scorpion toxins in the experiments performed with radioactive toxins. The rapid absorption of venom may be due to the low molecular weight toxins (4-7kDa) of this scorpion ([@CIT0006]; [@CIT0001]; [@CIT0002]). The fast absorption and distribution of the venom indicate that *O. doriae* envenomation is rapid. Therefore, specific and symptomatic treatments must be started as soon as possible after the sting, or else at least as soon as envenomation symptoms appear.

In a randomized controlled trial of scorpion antivenom therapy in Tunisia it was shown that the serotherapy against *Buthus occitanus tunetanus* scorpion was inefficient ([@CIT0003]). Although, this investigation was conducted on a small number of severely envenomed patients, it raises the question whether the dose of antivenom administered was less than the minimal required for neutralizing the toxic manifestations of the venom.

The IM route is still used in immunotherapy of scorpion envenoming. However, it is important to note that it results in a delayed neutralization of toxins that is 10-fold lower efficacy compared to the intravenous route ([@CIT0010]). Ismail and Abd-Elsalam concluded the IM injection of antivenoms is certainly ineffective in neutralizing the action of venoms, as the venoms and antivenom have no opportunity to meet quickly enough in the central or tissue compartments. But in this current study, the efficacy of used intramuscular route, dose and anticipated delay for antivenom administration indicate efficacious of immunotherapy with Razi antivenom. In support of this, [@CIT0022] reported that less than 40% of the intramuscularly injected antivenom F (ab′)2 are slowly absorbed from the injection site.

Iranian epidemiological data shows that 30% of the patients were taken to medical facilities more than 3hr after being stung by the scorpion, *H. lepturus* -- considered as the most dangerous scorpion in Iran ([@CIT0023]; [@CIT0015]). In other studies, a maximum distribution of the toxins and their complete neutralization in plasma were observed when the minimal efficient antivenom dose was injected 4-6hr after the envenomation. However, it is difficult to predict the clinical results of an antivenom immunotherapy when performed a long time after envenomation. Indeed, it is quite possible that the scorpion toxins may exert their deleterious effects and cause an irreversible damage before the administration of the antivenom.

CONCLUSIONS
===========

-   Immediate intramuscular administration of a dose of antivenom (human values corrected in experimental rat) has a favorable profile from kinetic and measured data view.

-   The intramuscular route administration of antivenom may be considered appropriate when administered within the gold time of 2hr.

-   IM injection may be suitable route for neutralization of *O. doriae* toxins with the available polyvalent antivenom prepared in the Razi Institute.
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